News

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade
I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...
SanDisk initiated, Analog Devices upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Managed Healthcare Executive2h
Study Suggests Respiratory Care Knowledge Gap Among DMD Caregivers
Many parents said they were afraid of noninvasive ventilation, with some citing inaccurate concerns about ventilation devices.
BioSpace5h
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys
Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...
Managed Healthcare Executive21h
NDA Resubmitted for Investigational Dry Eye Therapy, Reproxalap
Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
BIO chair: U.S. has a ‘crisis’ on drug costs
The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.